{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:18:37Z","timestamp":1791818317914,"version":"4.3.4"},"reference-count":67,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5,22]]},"abstract":"<jats:sec>\n                  <jats:title>Abstrat<\/jats:title>\n                  <jats:p>MDM2 inhibitors are promising therapeutics for acute myeloid leukemia (AML) with wild-type TP53. Through an integrated analysis of functional genomic data from primary patient samples, we found that an MDM2 inhibitor, idasanutlin, like venetoclax, is ineffective against monocytic leukemia (French-American-British [FAB] subtype M4\/M5). To dissect the underlying resistance mechanisms, we explored both intrinsic and extrinsic factors. We found that monocytic leukemia cells express elevated levels of CEBPB, which promote monocytic differentiation, suppress CASP3 and CASP6, and upregulate MCL1, BCL2A1, and the interleukin (IL-1)\/tumor necrosis factor alpha (TNF-\u03b1)\/NF-\u03baB pathway members, thereby conferring drug resistance to a broad range of MDM2 inhibitors, BH3 mimetics, and venetoclax combinations. In addition, aberrant monocytes in M4\/M5 leukemia produce elevated levels of IL-1 and TNF-\u03b1, which promote monocytic differentiation and upregulate inflammatory cytokines and receptors, thereby extrinsically protecting leukemia blasts from venetoclax and MDM2 inhibition. Interestingly, IL-1\u03b2 and TNF-\u03b1 only increase CEBPB levels and protect M4\/M5 cells from these drugs but not M0\/M1 leukemia cells. Treatment with venetoclax and idasanutlin induces compensatory upregulation of CEBPB and the IL-1\/TNF-\u03b1\/NF-\u03baB pathway independent of the FAB subtype, indicating drug-induced compensatory protection mechanisms. The combination of venetoclax or idasanutlin with inhibitors that block the IL-1\/TNF-\u03b1 pathway demonstrates synergistic cytotoxicity in M4\/M5 AML. As such, we uncovered a targetable positive feedback loop that involves CEBPB, IL-1\/TNF-\u03b1, and monocyte differentiation in M4\/M5 leukemia and promotes both intrinsic and extrinsic drug resistance and drug-induced protection against venetoclax and MDM2 inhibitors.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2024028239","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T17:11:11Z","timestamp":1740589871000},"page":"2488-2506","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":19,"title":["A CEBPB\/IL-1\u03b2\/TNF-\u03b1 feedback loop drives drug resistance to venetoclax and MDM2 inhibitors in monocytic leukemia"],"prefix":"10.1182","volume":"145","author":[{"given":"Basil","family":"Allen","sequence":"first","affiliation":[{"name":"1Division of Oncological Sciences, Knight Cancer Institute, Oregon Health & Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Bottomly","sequence":"additional","affiliation":[{"name":"2Knight Cancer Institute, Oregon Health & Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"K\u00f6hnke","sequence":"additional","affiliation":[{"name":"3Division of Hematology, Department of Medicine, Cancer Institute and Institute of Stem Cell Biology and Regenerative Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6297-5036","authenticated-orcid":false,"given":"Anthony","family":"Wang","sequence":"additional","affiliation":[{"name":"1Division of Oncological Sciences, Knight Cancer Institute, Oregon Health & Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Yun","family":"Lin","sequence":"additional","affiliation":[{"name":"4Department of Cell, Developmental and Cancer Biology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Johnson","sequence":"additional","affiliation":[{"name":"5Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Kenna","sequence":"additional","affiliation":[{"name":"1Division of Oncological Sciences, Knight Cancer Institute, Oregon Health & Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastatia","family":"Streltsova","sequence":"additional","affiliation":[{"name":"1Division of Oncological Sciences, Knight Cancer Institute, Oregon Health & Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Martin","sequence":"additional","affiliation":[{"name":"1Division of Oncological Sciences, Knight Cancer Institute, Oregon Health & Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reid","family":"Chen","sequence":"additional","affiliation":[{"name":"1Division of Oncological Sciences, Knight Cancer Institute, Oregon Health & Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Savoy","sequence":"additional","affiliation":[{"name":"1Division of Oncological Sciences, Knight Cancer Institute, Oregon Health & Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9010-8167","authenticated-orcid":false,"given":"Nicola","family":"Long","sequence":"additional","affiliation":[{"name":"4Department of Cell, Developmental and Cancer Biology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Ryabinin","sequence":"additional","affiliation":[{"name":"2Knight Cancer Institute, Oregon Health & Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4762-389X","authenticated-orcid":false,"given":"Stephen E.","family":"Kurtz","sequence":"additional","affiliation":[{"name":"4Department of Cell, Developmental and Cancer Biology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8835-8928","authenticated-orcid":false,"given":"Christopher A.","family":"Eide","sequence":"additional","affiliation":[{"name":"5Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Carlos","sequence":"additional","affiliation":[{"name":"6Massively Parallel Sequencing Shared Resource, Knight Cancer Institute, Oregon Health & Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Kaempf","sequence":"additional","affiliation":[{"name":"7Biostatistics Shared Resource, Knight Cancer Institute, Oregon Health & Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1695-8649","authenticated-orcid":false,"given":"Tingting","family":"Liu","sequence":"additional","affiliation":[{"name":"8Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Tognon","sequence":"additional","affiliation":[{"name":"5Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Searles","sequence":"additional","affiliation":[{"name":"6Massively Parallel Sequencing Shared Resource, Knight Cancer Institute, Oregon Health & Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5108-2227","authenticated-orcid":false,"given":"Paul D.","family":"Piehowski","sequence":"additional","affiliation":[{"name":"9Earth and Biological Sciences Directorate, Pacific Northwest National Laboratory, Richland, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6534-4774","authenticated-orcid":false,"given":"Sara J. C.","family":"Gosline","sequence":"additional","affiliation":[{"name":"9Earth and Biological Sciences Directorate, Pacific Northwest National Laboratory, Richland, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupriya","family":"Agarwal","sequence":"additional","affiliation":[{"name":"1Division of Oncological Sciences, Knight Cancer Institute, Oregon Health & Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3783-1820","authenticated-orcid":false,"given":"Bill H.","family":"Chang","sequence":"additional","affiliation":[{"name":"5Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4042-1374","authenticated-orcid":false,"given":"Michelle","family":"Barton","sequence":"additional","affiliation":[{"name":"1Division of Oncological Sciences, Knight Cancer Institute, Oregon Health & Science University, Portland, OR"},{"name":"10Cancer Early Detection Advanced Research Center, Oregon Health & Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8331-8206","authenticated-orcid":false,"given":"Brian J.","family":"Druker","sequence":"additional","affiliation":[{"name":"1Division of Oncological Sciences, Knight Cancer Institute, Oregon Health & Science University, Portland, OR"},{"name":"5Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8333-6607","authenticated-orcid":false,"given":"Shannon K.","family":"McWeeney","sequence":"additional","affiliation":[{"name":"2Knight Cancer Institute, Oregon Health & Science University, Portland, OR"},{"name":"11Division of Bioinformatics and Computational Biology, Department of Medical Informatics and Clinical Epidemiology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindra","family":"Majeti","sequence":"additional","affiliation":[{"name":"3Division of Hematology, Department of Medicine, Cancer Institute and Institute of Stem Cell Biology and Regenerative Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2133-0960","authenticated-orcid":false,"given":"Jeffrey W.","family":"Tyner","sequence":"additional","affiliation":[{"name":"4Department of Cell, Developmental and Cancer Biology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0749-9866","authenticated-orcid":false,"given":"Haijiao","family":"Zhang","sequence":"additional","affiliation":[{"name":"1Division of Oncological Sciences, Knight Cancer Institute, Oregon Health & Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"28","key":"2025052211211834000_bib1","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1038\/onc.2016.502","article-title":"Census and evaluation of p53 target genes","volume":"36","author":"Fischer","year":"2017","journal-title":"Oncogene"},{"issue":"22","key":"2025052211211834000_bib2","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.4161\/cc.26806","article-title":"Tumor suppression: putting p53 in context","volume":"12","author":"Mills","year":"2013","journal-title":"Cell Cycle"},{"issue":"6","key":"2025052211211834000_bib3","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.cell.2017.08.028","article-title":"Putting p53 in context","volume":"170","author":"Kastenhuber","year":"2017","journal-title":"Cell"},{"issue":"6630","key":"2025052211211834000_bib4","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/387299a0","article-title":"Regulation of p53 stability by Mdm2","volume":"387","author":"Kubbutat","year":"1997","journal-title":"Nature"},{"issue":"6630","key":"2025052211211834000_bib5","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/387296a0","article-title":"Mdm2 promotes the rapid degradation of p53","volume":"387","author":"Haupt","year":"1997","journal-title":"Nature"},{"issue":"6","key":"2025052211211834000_bib6","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1182\/blood-2017-02-763086","article-title":"Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy","volume":"130","author":"Prokocimer","year":"2017","journal-title":"Blood"},{"issue":"9","key":"2025052211211834000_bib7","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1182\/blood.V84.9.3158.3158","article-title":"The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin","volume":"84","author":"Watanabe","year":"1994","journal-title":"Blood"},{"issue":"5","key":"2025052211211834000_bib8","doi-asserted-by":"crossref","first-page":"a026245","DOI":"10.1101\/cshperspect.a026245","article-title":"Targeting the MDM2-p53 protein-protein interaction for new cancer therapy: progress and challenges","volume":"7","author":"Wang","year":"2017","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"3","key":"2025052211211834000_bib9","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1021\/jm501092z","article-title":"Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 inhibitors) in clinical trials for cancer treatment","volume":"58","author":"Zhao","year":"2015","journal-title":"J Med Chem"},{"issue":"6","key":"2025052211211834000_bib10","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1158\/1535-7163.MCT-20-0666","article-title":"High-throughput screening identifies idasanutlin as a resensitizing drug for venetoclax-resistant neuroblastoma cells","volume":"20","author":"Vernooij","year":"2021","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"2025052211211834000_bib11","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.3324\/haematol.2015.139717","article-title":"Clinical response to idasanutlin (RG7388) in acute myeloid leukemia patients is associated with pre-treatment MDM2 protein expression in leukemic blasts and leukemic stem cells","volume":"101","author":"Reis","year":"2016","journal-title":"Haematologica"},{"issue":"1","key":"2025052211211834000_bib12","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13045-016-0280-3","article-title":"Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models","volume":"9","author":"Lehmann","year":"2016","journal-title":"J Hematol Oncol"},{"key":"2025052211211834000_bib13","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.2147\/OTT.S172315","article-title":"MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388)","volume":"12","author":"Khurana","year":"2019","journal-title":"Onco Targets Ther"},{"issue":"3","key":"2025052211211834000_bib14","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00280-018-3534-7","article-title":"Phase 1 summary of plasma concentration\u2013QTc analysis for idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors and AML","volume":"81","author":"Blotner","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"2025052211211834000_bib15","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1182\/blood.2018893545","article-title":"Oral idasanutlin in patients with polycythemia vera","volume":"134","author":"Mascarenhas","year":"2019","journal-title":"Blood"},{"issue":"suppl 15","key":"2025052211211834000_bib16","doi-asserted-by":"crossref","first-page":"TPS7063","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS7063","article-title":"MIRROS: an ongoing randomized phase 3 trial of idasanutlin + ARA-C in patients with relapsed or refractory acute myeloid leukemia","volume":"37","author":"Montesinos","year":"2019","journal-title":"J Clin Oncol"},{"issue":"5","key":"2025052211211834000_bib17","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1200\/JCO.1990.8.5.813","article-title":"Report of the national cancer institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia","volume":"8","author":"Cheson","year":"1990","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025052211211834000_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V60.1.1.1","article-title":"Immunologic classification of leukemia and lymphoma","volume":"68","author":"Foon","year":"1986","journal-title":"Blood"},{"issue":"20","key":"2025052211211834000_bib19","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"7","key":"2025052211211834000_bib20","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"10","key":"2025052211211834000_bib21","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1182\/bloodadvances.2021006307","article-title":"Associating drug sensitivity with differentiation status identifies effective combinations for acute myeloid leukemia","volume":"6","author":"Kurtz","year":"2022","journal-title":"Blood Adv"},{"issue":"3","key":"2025052211211834000_bib22","doi-asserted-by":"crossref","first-page":"708","DOI":"10.3324\/haematol.2018.214882","article-title":"Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia","volume":"105","author":"Kuusanm\u00e4ki","year":"2020","journal-title":"Haematologica"},{"issue":"4","key":"2025052211211834000_bib23","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","article-title":"Monocytic subclones confer resistance to venetoclax-based therapy in acute myeloid leukemia patients","volume":"10","author":"Pei","year":"2020","journal-title":"Cancer Discov"},{"issue":"5","key":"2025052211211834000_bib24","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1158\/2643-3230.BCD-21-0012","article-title":"Monocytic differentiation and AHR signaling as primary nodes of BET inhibitor response in acute myeloid leukemia","volume":"2","author":"Romine","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"suppl 1","key":"2025052211211834000_bib25","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1182\/blood-2018-175","article-title":"Biomarkers predicting venetoclax sensitivity and strategies for venetoclax combination treatment","volume":"132","author":"Zhang","year":"2018","journal-title":"Blood"},{"issue":"8","key":"2025052211211834000_bib26","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/s43018-020-0103-x","article-title":"Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia","volume":"1","author":"Zhang","year":"2020","journal-title":"Nat Cancer"},{"issue":"suppl 1","key":"2025052211211834000_bib27","doi-asserted-by":"crossref","first-page":"8778","DOI":"10.1182\/blood-2022-157622","article-title":"Characterize biomarkers and mechanisms of resistance for MDM2 inhibitors in AML","volume":"140","author":"Savoy","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2025052211211834000_bib28","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/bjh.18843","article-title":"CDK12\/13 dual inhibitors are potential therapeutics for acute myeloid leukemia","volume":"202","author":"Savoy","year":"2023","journal-title":"Br J Haematol"},{"key":"2025052211211834000_bib29","doi-asserted-by":"crossref","first-page":"824562","DOI":"10.3389\/fonc.2022.824562","article-title":"Acute myeloid leukemia cells functionally compromise hematopoietic stem\/progenitor cells inhibiting normal hematopoiesis through the release of extracellular vesicles","volume":"12","author":"Trino","year":"2022","journal-title":"Front Oncol"},{"issue":"5","key":"2025052211211834000_bib30","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0145-2126(98)00024-1","article-title":"Cytokine gene activity in AML cells in vivo in patients","volume":"22","author":"Gao","year":"1998","journal-title":"Leuk Res"},{"issue":"3","key":"2025052211211834000_bib31","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.scr.2015.09.008","article-title":"The cytokine-mediated crosstalk between primary human acute myeloid cells and mesenchymal stem cells alters the local cytokine network and the global gene expression profile of the mesenchymal cells","volume":"15","author":"Reikvam","year":"2015","journal-title":"Stem Cell Res"},{"issue":"13","key":"2025052211211834000_bib32","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1016\/j.celrep.2017.03.018","article-title":"Identification of interleukin-1 by functional screening as a key mediator of cellular expansion and disease progression in acute myeloid leukemia","volume":"18","author":"Carey","year":"2017","journal-title":"Cell Rep"},{"issue":"1","key":"2025052211211834000_bib33","doi-asserted-by":"crossref","first-page":"101359","DOI":"10.1016\/j.xcrm.2023.101359","article-title":"Mapping the proteogenomic landscape enables prediction of drug response in acute myeloid leukemia","volume":"5","author":"Pino","year":"2024","journal-title":"Cell Rep Med"},{"issue":"8","key":"2025052211211834000_bib34","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.ccell.2022.07.002","article-title":"Integrative analysis of drug response and clinical outcome in acute myeloid leukemia","volume":"40","author":"Bottomly","year":"2022","journal-title":"Cancer Cell"},{"issue":"7728","key":"2025052211211834000_bib35","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","article-title":"Functional genomic landscape of acute myeloid leukaemia","volume":"562","author":"Tyner","year":"2018","journal-title":"Nature"},{"issue":"4","key":"2025052211211834000_bib36","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1182\/blood.2024024968","article-title":"Ex vivo venetoclax sensitivity predicts clinical response in acute myeloid leukemia in the prospective VenEx trial","volume":"145","author":"Kyt\u00f6l\u00e4","year":"2025","journal-title":"Blood"},{"issue":"4","key":"2025052211211834000_bib37","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1182\/blood.2024027054","article-title":"VenEx precisely predicts ven-aza response","volume":"145","author":"Becker","year":"2025","journal-title":"Blood"},{"issue":"1","key":"2025052211211834000_bib38","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41698-021-00209-9","article-title":"Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia","volume":"5","author":"White","year":"2021","journal-title":"NPJ Precis Oncol"},{"issue":"4","key":"2025052211211834000_bib39","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","article-title":"Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia","volume":"10","author":"Pei","year":"2020","journal-title":"Cancer Discov"},{"issue":"13","key":"2025052211211834000_bib40","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1182\/blood.2022016033","article-title":"Proteomic and phosphoproteomic landscapes of acute myeloid leukemia","volume":"140","author":"Kramer","year":"2022","journal-title":"Blood"},{"issue":"D1","key":"2025052211211834000_bib41","doi-asserted-by":"crossref","first-page":"D881","DOI":"10.1093\/nar\/gky1076","article-title":"BloodSpot: a database of healthy and malignant haematopoiesis updated with purified and single cell mRNA sequencing profiles","volume":"47","author":"Bagger","year":"2019","journal-title":"Nucleic Acids Res"},{"issue":"suppl 16","key":"2025052211211834000_bib42","doi-asserted-by":"crossref","first-page":"5942","DOI":"10.1158\/1538-7445.AM2020-5942","article-title":"Abstract 5942: an integrated approach reveals novel extrinsic pathways and cytokine signatures associated with drug response in acute myeloid leukemia","volume":"80","author":"Modak","year":"2020","journal-title":"Cancer Res"},{"issue":"1","key":"2025052211211834000_bib43","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13045-020-00941-y","article-title":"A single-cell survey of cellular hierarchy in acute myeloid leukemia","volume":"13","author":"Wu","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"8","key":"2025052211211834000_bib44","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1038\/sj.leu.2401865","article-title":"Death and decoy receptors and p53-mediated apoptosis","volume":"14","author":"Sheikh","year":"2000","journal-title":"Leukemia"},{"issue":"12","key":"2025052211211834000_bib45","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1158\/1535-7163.MCT-10-0646","article-title":"Contrasting effects of nutlin-3 on TRAIL- and docetaxel-induced apoptosis due to upregulation of TRAIL-R2 and Mcl-1 in human melanoma cells","volume":"9","author":"Tseng","year":"2010","journal-title":"Mol Cancer Ther"},{"issue":"10","key":"2025052211211834000_bib46","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1038\/bjc.2013.636","article-title":"Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL","volume":"109","author":"Meijer","year":"2013","journal-title":"Br J Cancer"},{"issue":"3","key":"2025052211211834000_bib47","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.trecan.2020.10.005","article-title":"Life and death decision-making by p53 and implications for cancer immunotherapy","volume":"7","author":"Liu","year":"2021","journal-title":"Trends Cancer"},{"issue":"12","key":"2025052211211834000_bib48","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1101\/gad.12.12.1907","article-title":"The C\/EBP\u03b2 transcription factor regulates epithelial cell proliferation and differentiation in the mammary gland","volume":"12","author":"Robinson","year":"1998","journal-title":"Genes Dev"},{"issue":"17","key":"2025052211211834000_bib49","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1101\/gad.11.17.2153","article-title":"An essential role for C\/EBP\u03b2 in female reproduction","volume":"11","author":"Sterneck","year":"1997","journal-title":"Genes Dev"},{"issue":"14","key":"2025052211211834000_bib50","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/bloodadvances.2018022913","article-title":"C\/EBP\u03b2 isoforms regulate proliferation and differentiation of regenerating hematopoietic stem\/progenitor cells","volume":"4","author":"Sato","year":"2020","journal-title":"Blood Adv"},{"issue":"44","key":"2025052211211834000_bib51","doi-asserted-by":"crossref","first-page":"28545","DOI":"10.1074\/jbc.273.44.28545","article-title":"Biological role of the CCAAT\/enhancer-binding protein family of transcription factors","volume":"273","author":"Lekstrom-Himes","year":"1998","journal-title":"J Biol Chem"},{"issue":"2","key":"2025052211211834000_bib52","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/0092-8674(95)90418-2","article-title":"Targeted disruption of the NF-IL6 gene discloses its essential role in bacteria killing and tumor cytotoxicity by macrophages","volume":"80","author":"Tanaka","year":"1995","journal-title":"Cell"},{"issue":"45","key":"2025052211211834000_bib53","doi-asserted-by":"crossref","first-page":"29279","DOI":"10.1074\/jbc.273.45.29279","article-title":"The role of C\/EBP isoforms in the control of inflammatory and native immunity functions","volume":"273","author":"Poli","year":"1998","journal-title":"J Biol Chem"},{"issue":"46","key":"2025052211211834000_bib54","doi-asserted-by":"crossref","first-page":"30057","DOI":"10.1074\/jbc.273.46.30057","article-title":"The role of C\/EBP genes in adipocyte differentiation","volume":"273","author":"Darlington","year":"1998","journal-title":"J Biol Chem"},{"issue":"42","key":"2025052211211834000_bib55","doi-asserted-by":"crossref","first-page":"26306","DOI":"10.1074\/jbc.272.42.26306","article-title":"Role of the isoforms of CCAAT\/enhancer-binding protein in the initiation of phosphoenolpyruvate carboxykinase (GTP) gene transcription at birth","volume":"272","author":"Croniger","year":"1997","journal-title":"J Biol Chem"},{"issue":"1","key":"2025052211211834000_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0163-7258(03)00070-6","article-title":"Alternate interferon signaling pathways","volume":"100","author":"Kalvakolanu","year":"2003","journal-title":"Pharmacol Ther"},{"issue":"7","key":"2025052211211834000_bib57","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/ni1354","article-title":"C\/EBP\u03b2 is required for \u201cemergency\u201d granulopoiesis","volume":"7","author":"Hirai","year":"2006","journal-title":"Nat Immunol"},{"issue":"9","key":"2025052211211834000_bib58","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/ncb3397","article-title":"NOTCH1 mediates a switch between two distinct secretomes during senescence","volume":"18","author":"Hoare","year":"2016","journal-title":"Nat Cell Biol"},{"issue":"1","key":"2025052211211834000_bib59","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/(SICI)1098-1136(20000101)29:1<91::AID-GLIA9>3.0.CO;2-I","article-title":"Pro-inflammatory cytokines induce the transcription factors C\/EBP\u03b2 and C\/EBP\u03b4 in astrocytes","volume":"29","author":"Cardinaux","year":"2000","journal-title":"Glia"},{"issue":"6","key":"2025052211211834000_bib60","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.immuni.2010.05.010","article-title":"Tumor-induced tolerance and immune suppression depend on the C\/EBP\u03b2 transcription factor","volume":"32","author":"Marigo","year":"2010","journal-title":"Immunity"},{"issue":"5","key":"2025052211211834000_bib61","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/cmi.2009.45","article-title":"MicroRNA-155 regulates inflammatory cytokine production in tumor-associated macrophages via targeting C\/EBP\u03b2","volume":"6","author":"He","year":"2009","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"2025052211211834000_bib62","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/jcsm.12909","article-title":"C\/EBP\u03b2 promotes the expression of atrophy-inducing factors by tumours and is a central regulator of cancer cachexia","volume":"13","author":"AlSudais","year":"2022","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"1","key":"2025052211211834000_bib63","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s40425-019-0701-2","article-title":"Colorectal cancer cell-derived CCL20 recruits regulatory T cells to promote chemoresistance via FOXO1\/CEBPB\/NF-\u03baB signaling. [published correction appears in J Immunother Cancer. 2022 Jun;10(6):e0701-2corr1]","volume":"7","author":"Wang","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"23","key":"2025052211211834000_bib64","doi-asserted-by":"crossref","first-page":"6362","DOI":"10.1158\/1078-0432.CCR-20-1762","article-title":"The capacity of the ovarian cancer tumor microenvironment to integrate inflammation signaling conveys a shorter disease-free interval","volume":"26","author":"Jordan","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2025052211211834000_bib65","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1182\/blood.V81.11.3091.3091","article-title":"High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy","volume":"81","author":"Campos","year":"1993","journal-title":"Blood"},{"issue":"6","key":"2025052211211834000_bib66","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.ccell.2017.11.003","article-title":"Synthetic lethality of combined Bcl-2 inhibition and p53 activation in AML: mechanisms and superior antileukemic efficacy","volume":"32","author":"Pan","year":"2017","journal-title":"Cancer Cell"},{"issue":"15","key":"2025052211211834000_bib67","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1101\/gad.8.15.1739","article-title":"Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential","volume":"8","author":"Barak","year":"1994","journal-title":"Genes Dev"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/21\/2488\/2375326\/blood_bld-2024-028239-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/21\/2488\/2375326\/blood_bld-2024-028239-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T15:21:32Z","timestamp":1747927292000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/145\/21\/2488\/535765\/A-CEBPB-IL-1-TNF-feedback-loop-drives-drug"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":67,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2025,5,22]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024028239","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5,22]]},"published":{"date-parts":[[2025,5,22]]}}}